Innovate UK, part of UK Research and Innovation, will invest up to £5.4 million. This is for innovation projects that use whole genome sequencing to analyse cancers. This competition is funded through the Industrial Strategy Challenge Fund.
The aim is to encourage the development of new approaches to targeted therapy based on the molecular signatures of cancers. Your project can develop new analytical methods or validate new targets using new and existing genomic data from cancers.
We will fund feasibility studies, industrial research and experimental development.
The aim of this competition is to support projects that involve the use of whole genome sequencing to analyse cancer.
Your project must work with whole genome sequence data. This can be through the manipulation of existing whole genome data, through the collection of other whole genome sequences or through both of these. Possible approaches include but are not limited to:
- the development of new analytical or reporting tools for clinical decision support
- the identification of molecular signatures that allow for new or improved targeting of therapies
- the identification of new therapeutic targets
- new genetic signatures that can be used clinically, such as markers that support repurposing of drugs or a personalised approach to patient management
- the comparative assessment of alternative assay methods in parallel with whole genome sequencing
We expect projects that generate new whole genome sequence data to make this data available within as part of the dataset held by Genomics England at the end of the project.
We are looking to fund a portfolio of projects, across a variety of technologies, markets, technological maturities and research categories.